| Cat. No. |
Product Name |
Information |
| PC-24736 |
WMJ-J-09
HDAC inhibitor
|
WMJ-J-09 a potent, hydroxamate based HDAC inhibitor, exhibits potent inhibitory activity against class I HDACs, including HDAC1 (IC50=7.5 nM), HDAC2 (IC50=21.3 nM), HDAC3 (IC50=18.4 nM), and HDAC8 (IC50=90.9 nM), also strongly inhibitsHDAC6 (class IIb) with IC50 of 3.9 nM. |
| PC-24698 |
PAT-1102
HDAC inhibitor
|
PAT-1102 (FNDR-20123) is a novel, potent, orally available HDAC inhibitor with IC50 of 3 nM in cell-free HDAC enzymatic assays, also inhibits Plasmodium HDAC with IC50 of 31 nM. |
| PC-24619 |
Bisthianostat
HDAC inhibitor
|
Bisthianostat (CF367) is an orally bioavailable pan-inhibitor of human histone deacetylase (HDAC) with IC50 of 0.07, 0.26 and 0.79 uM for HDAC1, HDAC2 and HDAC6 respectively. |
| PC-24425 |
DDI199
HDAC/ChE/MAO inhibitor
|
DDI199 (Contilistat) is a novel multi-target molecule by linking Contilisant and Vorinostat (SAHA), inhibits histone deacetylases (HDACs), monoamine oxidases (MAOs) and cholinesterases (ChEs), and modulate histamine H3 (H3R) and Sigma 1 Receptor (S1R) receptors, shows anti-tumor activity against glioma stem cells (GSCs). |
| PC-24229 |
HDAC6 inhibitor FDR2
HDAC6 inhibitor
|
HDAC6 inhibitor FDR2 is a selective small molecule HDAC6 inhibitor with IC50 of 50.8 nM, shows >100-fold selectivity over HDAC1. |
| PC-24228 |
HDAC6 inhibitor DR-3
HDAC6 inhibitor
|
HDAC6 inhibitor DR-3 is a selective small molecule HDAC6 inhibitor with IC50 of 78.1 nM, shows 100-fold selectivity over HDAC1. |
| PC-24027 |
SR-4370
HDAC inhibitor
|
SR-4370 is a novel HDAC inhibitor with IC50 of 0.13/0.5/0.006/3.4/2.3 μM for HDAC1/2/3/6/8, respectively, also is a latency-reversing agent (LRA) for reactivation of latent HIV-1. |
| PC-24022 |
HDAC11 inhibitor B6
HDAC11 inhibitor
|
HDAC11 inhibitor B6 is a potent, highly selective HDAC11 inhibitor with IC50 of 51.1 nM, >90-fold selective over HDAC8 and shows no activity against all other HDAC subtypes. |
| PC-23991 |
IHCH9033
class I HDAC inhibitor
|
IHCH9033 is a selective, triazole-containing class I HDAC inhibitor, exhibits an increased antitumor effect in FLT3-ITD AML through effectively eliminating leukemia burden and overcoming resistance to FLT3i. |
| PC-23970 |
RG2833
HDAC1/3 inhibitor
|
RG2833 is a potent, orally bioavailable, brain-penetrant histone deacetylase HDAC1/3 inhibitor with IC50 of 60/50 mM respectively. |
| PC-23965 |
HDAC3 inhibitor LSQ-28
HDAC3 inhibitor
|
LSQ-28 is a potent, selective HDAC3 inhibitor with IC50 of 42 nM, >150-fold selective over HDAC1, HDAC2, and HDAC6. |
| PC-23806 |
NSC3852
HDAC inhibitor
|
NSC3852 is a small molecule inhibitor of histone deacetylase (HDAC) with cell differentiation and antiproliferative activity in human breast cancer cells, synergistically enhances the cytotoxicity of olaparib in oral squamous cell carcinoma. |
